Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children

Bert Bakker, James Frane, Henry Anhalt, Barbara Lippe, Ronald (Ron) Rosenfeld

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Context: Although GH has been used to treat short stature in GH deficiency (GHD) and other conditions for more than 40 yr, criteria for satisfactorily defining targets for GH responsiveness have never been developed. Objective: The objective of this study was to present the first-year growth expressed as height velocity (HV) for prepubertal boys and girls with idiopathic GHD, organic GHD, idiopathic short stature, or Turner syndrome from Genentech's National Cooperative Growth Study to derive age-specific targets for GH responsiveness for each etiology and gender. Design and Population: Using data from the National Cooperative Growth Study, we constructed curves of response to GH during the first year of treatment with standard daily doses in naive-totreatment prepubertal children with idiopathic GHD (2323 males, 842 females), organic GHD (582 males, 387 females), idiopathic short stature (1392 males, 465 females), or Turner syndrome (1367 females). Main Outcome Measure: For each category, mean pretreatment and mean ±1 and ±2 SD for the first-year HV on GH were assessed. Mean and mean ± 1 SD for HV were plotted vs. age at baseline (initiation of GH treatment) and compared with mean pretreatment HV. Results: HV plots for each category as a factor of age at baseline are presented. Mean - 2 SD HV plots approximated the pretreatment HV. Conclusion: Using baseline age- and gender-specific targets will assist clinicians in assessing a patient's first-year growth response. We propose that HV below the mean - 1 SD on these plots be considered a "poor" response. These curvesmaybe used to identify patients who may benefit from GH dose adjustment, to assess compliance issues, or to challenge the original diagnosis.

Original languageEnglish (US)
Pages (from-to)352-357
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume93
Issue number2
DOIs
StatePublished - Feb 2008
Externally publishedYes

Fingerprint

Growth Hormone
Turner Syndrome
Growth
Age Factors
Compliance
Outcome Assessment (Health Care)
Therapeutics
Population

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children. / Bakker, Bert; Frane, James; Anhalt, Henry; Lippe, Barbara; Rosenfeld, Ronald (Ron).

In: Journal of Clinical Endocrinology and Metabolism, Vol. 93, No. 2, 02.2008, p. 352-357.

Research output: Contribution to journalArticle

Bakker, Bert ; Frane, James ; Anhalt, Henry ; Lippe, Barbara ; Rosenfeld, Ronald (Ron). / Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children. In: Journal of Clinical Endocrinology and Metabolism. 2008 ; Vol. 93, No. 2. pp. 352-357.
@article{c57dcda58dd546dda90914c573394b10,
title = "Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children",
abstract = "Context: Although GH has been used to treat short stature in GH deficiency (GHD) and other conditions for more than 40 yr, criteria for satisfactorily defining targets for GH responsiveness have never been developed. Objective: The objective of this study was to present the first-year growth expressed as height velocity (HV) for prepubertal boys and girls with idiopathic GHD, organic GHD, idiopathic short stature, or Turner syndrome from Genentech's National Cooperative Growth Study to derive age-specific targets for GH responsiveness for each etiology and gender. Design and Population: Using data from the National Cooperative Growth Study, we constructed curves of response to GH during the first year of treatment with standard daily doses in naive-totreatment prepubertal children with idiopathic GHD (2323 males, 842 females), organic GHD (582 males, 387 females), idiopathic short stature (1392 males, 465 females), or Turner syndrome (1367 females). Main Outcome Measure: For each category, mean pretreatment and mean ±1 and ±2 SD for the first-year HV on GH were assessed. Mean and mean ± 1 SD for HV were plotted vs. age at baseline (initiation of GH treatment) and compared with mean pretreatment HV. Results: HV plots for each category as a factor of age at baseline are presented. Mean - 2 SD HV plots approximated the pretreatment HV. Conclusion: Using baseline age- and gender-specific targets will assist clinicians in assessing a patient's first-year growth response. We propose that HV below the mean - 1 SD on these plots be considered a {"}poor{"} response. These curvesmaybe used to identify patients who may benefit from GH dose adjustment, to assess compliance issues, or to challenge the original diagnosis.",
author = "Bert Bakker and James Frane and Henry Anhalt and Barbara Lippe and Rosenfeld, {Ronald (Ron)}",
year = "2008",
month = "2",
doi = "10.1210/jc.2007-1581",
language = "English (US)",
volume = "93",
pages = "352--357",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children

AU - Bakker, Bert

AU - Frane, James

AU - Anhalt, Henry

AU - Lippe, Barbara

AU - Rosenfeld, Ronald (Ron)

PY - 2008/2

Y1 - 2008/2

N2 - Context: Although GH has been used to treat short stature in GH deficiency (GHD) and other conditions for more than 40 yr, criteria for satisfactorily defining targets for GH responsiveness have never been developed. Objective: The objective of this study was to present the first-year growth expressed as height velocity (HV) for prepubertal boys and girls with idiopathic GHD, organic GHD, idiopathic short stature, or Turner syndrome from Genentech's National Cooperative Growth Study to derive age-specific targets for GH responsiveness for each etiology and gender. Design and Population: Using data from the National Cooperative Growth Study, we constructed curves of response to GH during the first year of treatment with standard daily doses in naive-totreatment prepubertal children with idiopathic GHD (2323 males, 842 females), organic GHD (582 males, 387 females), idiopathic short stature (1392 males, 465 females), or Turner syndrome (1367 females). Main Outcome Measure: For each category, mean pretreatment and mean ±1 and ±2 SD for the first-year HV on GH were assessed. Mean and mean ± 1 SD for HV were plotted vs. age at baseline (initiation of GH treatment) and compared with mean pretreatment HV. Results: HV plots for each category as a factor of age at baseline are presented. Mean - 2 SD HV plots approximated the pretreatment HV. Conclusion: Using baseline age- and gender-specific targets will assist clinicians in assessing a patient's first-year growth response. We propose that HV below the mean - 1 SD on these plots be considered a "poor" response. These curvesmaybe used to identify patients who may benefit from GH dose adjustment, to assess compliance issues, or to challenge the original diagnosis.

AB - Context: Although GH has been used to treat short stature in GH deficiency (GHD) and other conditions for more than 40 yr, criteria for satisfactorily defining targets for GH responsiveness have never been developed. Objective: The objective of this study was to present the first-year growth expressed as height velocity (HV) for prepubertal boys and girls with idiopathic GHD, organic GHD, idiopathic short stature, or Turner syndrome from Genentech's National Cooperative Growth Study to derive age-specific targets for GH responsiveness for each etiology and gender. Design and Population: Using data from the National Cooperative Growth Study, we constructed curves of response to GH during the first year of treatment with standard daily doses in naive-totreatment prepubertal children with idiopathic GHD (2323 males, 842 females), organic GHD (582 males, 387 females), idiopathic short stature (1392 males, 465 females), or Turner syndrome (1367 females). Main Outcome Measure: For each category, mean pretreatment and mean ±1 and ±2 SD for the first-year HV on GH were assessed. Mean and mean ± 1 SD for HV were plotted vs. age at baseline (initiation of GH treatment) and compared with mean pretreatment HV. Results: HV plots for each category as a factor of age at baseline are presented. Mean - 2 SD HV plots approximated the pretreatment HV. Conclusion: Using baseline age- and gender-specific targets will assist clinicians in assessing a patient's first-year growth response. We propose that HV below the mean - 1 SD on these plots be considered a "poor" response. These curvesmaybe used to identify patients who may benefit from GH dose adjustment, to assess compliance issues, or to challenge the original diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=39049171452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049171452&partnerID=8YFLogxK

U2 - 10.1210/jc.2007-1581

DO - 10.1210/jc.2007-1581

M3 - Article

C2 - 18000092

AN - SCOPUS:39049171452

VL - 93

SP - 352

EP - 357

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -